Q2 EPS Estimates for Tourmaline Bio Reduced by HC Wainwright

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at HC Wainwright cut their Q2 2025 EPS estimates for Tourmaline Bio in a research note issued to investors on Monday, May 5th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.91) per share for the quarter, down from their previous forecast of ($0.86). HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Tourmaline Bio's Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.95) EPS and Q4 2026 earnings at ($0.96) EPS.

Several other equities analysts also recently issued reports on the stock. Lifesci Capital assumed coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They set an "outperform" rating and a $58.00 price target for the company. Wedbush upped their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. Finally, Chardan Capital reissued a "buy" rating and issued a $70.00 price target on shares of Tourmaline Bio in a report on Monday, May 5th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Price Performance

TRML traded up $0.83 during trading on Wednesday, hitting $15.93. The company had a trading volume of 41,130 shares, compared to its average volume of 322,961. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The business has a 50-day moving average of $15.49 and a 200-day moving average of $18.65. The company has a market cap of $409.24 million, a PE ratio of -5.65 and a beta of 2.11.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.02.

Hedge Funds Weigh In On Tourmaline Bio

A number of large investors have recently made changes to their positions in TRML. Rhumbline Advisers boosted its position in Tourmaline Bio by 2.1% during the fourth quarter. Rhumbline Advisers now owns 35,591 shares of the company's stock worth $722,000 after purchasing an additional 718 shares during the period. SG Americas Securities LLC boosted its position in Tourmaline Bio by 3.4% during the fourth quarter. SG Americas Securities LLC now owns 34,812 shares of the company's stock worth $706,000 after purchasing an additional 1,140 shares during the period. Invesco Ltd. boosted its position in Tourmaline Bio by 10.8% during the fourth quarter. Invesco Ltd. now owns 12,155 shares of the company's stock worth $247,000 after purchasing an additional 1,181 shares during the period. Tower Research Capital LLC TRC boosted its position in Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after purchasing an additional 1,232 shares during the period. Finally, Brooklyn Investment Group bought a new stake in Tourmaline Bio during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 91.89% of the company's stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.